Abstract
Since 1958, cell culture media supplemented with fetal bovine serum is used, despite the well-known concerns about animal welfare, reproducibility, reliability, relevance, and safety. To obliterate these concerns and increase scientific accuracy, we recently published an open access, publicly available paper on a defined medium composition to make it possible for any lab to prepare this medium. The medium supports routine culturing and cell banking as well as investigations of growth curves, dose response testing of compounds of cells in 2D and 3D, and cell migration; all important aspects for research and toxicology. Here we give a detailed description of how to mix the defined universal cell culture medium in 14 simple steps to support any entity that wishes to make it. We also list different normal and cancer cell lines that have been cultured in the defined medium.
-
•
Open source composition of animal product free universal cell culture medium
-
•
Protocols for mixing solutions of small xeno free molecules for supplementation
-
•
Protocols for mixing solutions of human proteins for supplementation
Keywords: Defined medium, Cell culture, Reproducible composition, Human proteins, Ethically acceptable, Animal free medium
Method name: Protocols for mixing animal product free defined cell culture medium
Graphical abstract
Specifications table
| Subject area: | Pharmacology, Toxicology and Pharmaceutical Science |
| More specific subject area: | Animal product free defined cell culture medium |
| Name of your method: | Protocols for mixing animal product free defined cell culture medium |
| Name and reference of original method: | A new animal product free defined medium for 2D and 3D culturing of normal and cancer cells to study cell proliferation and migration as well as dose response to chemical treatment https://doi.org/10.1016/j.toxrep.2023.04.001 |
| Resource availability: | Vendors and product information in the protocols |
Method details
Since cells are cultured in vitro, the search for an optimal culture medium is ongoing [1]. So far, the use of media supplemented with mammal-based serum ingredients is an often taken choice [2], [3], [4]. These are mostly of bovine or human origins, like fetal bovine serum (FBS) and human platelet lysate (hPL), respectively. However, these supplements are undefined, characterized by batch-to-batch variability, may induce a non-physiological, proliferating cellular phenotype, and bare the risk of contamination or even infections [5,6]. Together, this negatively affects safety, relevance, and reproducibility of research outcomes [7], [8], [9]. Especially, when culturing e.g. human cells in a non-human medium like FBS-supplemented medium, the transferability of the experimental results is questionable. Furthermore, it is an ethical necessity to replace animal-derived ingredients like FBS in the laboratory to maximize animal welfare [10], [11], [12], [13].
In 2023, Rafnsdóttir et al. published a paper on a defined, safe to use, animal free, and universally usable cell culture medium [14]. Table 1 lists the cell lines that were used in the published paper. Table 2 shows a list of different cancer and normal cell lines that since then have been adapted to the medium and that have been routine-cultured to ascertain stable growth. Presently we are performing experiments with HeLa, MCF-7, and MCF-10A cells (not published yet). Also, a number of dose response experiments have been performed with the pancreatic cancer cells lines (not published yet).
Table 1.
Compilation of cell lines cultured in the defined medium described in Rafnsdóttir et al.[14].
| Cell line name | Characterisation | Provider | Product number |
|---|---|---|---|
| CaCo-2 | Human colon cancer | ATCCa | HTB-37 |
| Cancer-associated fibroblasts | Human fibroblasts | Kojima et al., 2010 [15] | — |
| JIMT-1 | Human breast cancer | DSMZb | ACC589 |
| KeratinoSens | Human keratinocytes | acCCELLeratec | RE242 |
| L929 | Mouse fibroblasts | ATCC | CCL-1 |
| MDA-MB-231 | Human breast cancer | ATCC | HTB-26 |
| MiaPaCa-2 | Human pancreatic cancer | ATCC | CRL-1420 |
American Type Culture Collection, Manassas, Virginia, USA. https://www.atcc.org/.
Deutsche Sammlung von Mikroorganismen und Zellkulturen (German Collection of Microorganisms and Cell Cultures), Braunschweig, Germany. https://www.dsmz.de/.
Hamburg, Germany. https://www.accellerate.me/.
Table 2.
Compilation of cell lines cultured in the defined medium, unpublished.
| Cell line name | Characterisation | Provider | Product number |
|---|---|---|---|
| AsPC-1 | Human pancreatic cancer | ATCC | CRL-1682 |
| BxPC-3 | Human pancreatic cancer | ATCC | CRL-1687 |
| C6 | Rat glioma | ATCC | CCL-107 |
| CaOv-3 | Human ovarian cancer | ATCC | HTB-75 |
| HDF, adult | Human dermal fibroblasts, adult | Sigma-Aldricha | 106-05A |
| HeLa | Human cervical cancer | ATCC | CRM-CCL-2 |
| LAN-1 | Human neuroblastoma | DSMZ | ACC 655 |
| MCF-7 | Human breast cancer | ATCC | HTB-22 |
| MCF-10A | “Normal-like” human breast epithelial | ATCC | CRL-10317 |
| NmuMg | Mouse mammary gland epithelial | ATCC | CRL-1636 |
| PanC-1 | Human pancreatic cancer | ATCC | CRL-1469 |
Sigma-Aldrich Sweden AB, Stockholm, Sweden. https://www.sigmaaldrich.com/.
Here we provide a detailed protocol on how to prepare the defined medium. After the stock solutions of the components are prepared, the medium can be mixed by following only 14 simple steps. This protocol is using human-derived proteins, as well as human recombinant proteins in accordance with our publication Rafnsdóttir et al. [14]. However, it should be possible to use only recombinant proteins (e.g. recombinant human serum albumin [16]) to even further increase reproducibility.
In addition, although the medium has been used for a variety of cell lines and we define it as universal, we hope this can be a starting point for abandoning the use of FBS and for further refinement to more exactly reproduce the human cellular environment.
Important information before preparation of the medium
Prior to the actual mixing of the defined medium, different phases have to be taken according to Fig. 1. First, purchase all components needed for the medium. The company products displayed below are suggestions. Products with similar properties from different providers than listed here can be used for the preparation of the medium as well, e.g. human serum albumin from SeraCare1 (product number 1850-0028) or human placenta laminin [17] from THT Biomaterials2 (product number THT0201), instead of those listed below in Tables 4 and 5.
Fig. 1.
Schematic presentation of the phases of the medium preparation.
Table 4.
Components stored at −20 °C.
| Component | Preparation | Provider | Product number |
|---|---|---|---|
| L-Glutamine | Purchased | Sigma-Aldrich | G7513-100ML |
| Non-essential amino acids (NEAA) | Purchased | Sigma-Aldrich | M7145-100ML |
| Sodium pyruvate | Purchased | Sigma-Aldrich | S8636-100ML |
| Antibiotics (penicillin-streptomycin) | Purchased | Sigma-Aldrich | P0781-100ML |
| Fibronectin | See Table 18: Preparation of the fibronectin solution. | EMD Millipore Corporationa | FC010-10MG |
| Transferrin | See Table 23: Preparation of the transferrin solution. | Sigma-Aldrich | T3705-1G |
| Human serum albumin (HSA) | See Table 25: Preparation of the human serum albumin (HSA) solution for the defined medium and Table 19: Preparation of PBS with 0.1 % human serum albumin (HSA). | Biowest | P6140 |
Subsidiary of Merck KGaA, Darmstadt, Germany. https://www.emdmillipore.com/.
Table 5.
Components stored (aliquoted in Eppendorf tubes together in plastic bags) at −80 °C.
| Component | Preparation | Provider | Product number | |
|---|---|---|---|---|
| Ethanol solution | 4-Aminobenzoic acid | See Table 7: Preparation of the ethanol solution. | Sigma-Aldrich | A9878 |
| Cholesterol | Sigma-Aldrich | C3045 | ||
| Lipoic acid | Sigma-Aldrich | 07039-10MG | ||
| Linoleic acid | Sigma-Aldrich | L1012 | ||
| NaOH solution | Folic acid | See Table 8: Preparation of the NaOH solution. | Sigma-Aldrich | F8758 |
| Uracil | Sigma-Aldrich | U1128 | ||
| Xanthine | Sigma-Aldrich | X3627 | ||
| H2O solution | Ascorbic acid | See Table 9: Preparation of the H2O solution. | Sigma-Aldrich | A4403 |
| Choline chloride | Sigma-Aldrich | C7527 | ||
| Glutathione | Sigma-Aldrich | G6013 | ||
| I-Inositol | Sigma-Aldrich | I7508 | ||
| O-Phosphorylethanolamine | Sigma-Aldrich | P0503 | ||
| Ribose | Sigma-Aldrich | R9629 | ||
| Selenous acid | Sigma-Aldrich | 211176 | ||
| Thiamine hydrochloride | Sigma-Aldrich | T1270 | ||
| α-Tocopherol phosphate | Sigma-Aldrich | T2020 | ||
| Vitamin B12 | Sigma-Aldrich | V6629 | ||
| All-trans retinoic acid | See Table 10: Preparation of the all-trans retinoic acid solution. | Sigma-Aldrich | R2625-50mg | |
| β-Estradiol | See Table 11: Preparation of the β-estradiol solution. | Sigma-Aldrich | E2758-250MG | |
| Hydrocortisone | See Table 12: Preparation of the hydrocortisone solution. | Sigma-Aldrich | H0888 | |
| Triiodothyronine | See Table 13: Preparation of the triiodothyronine solution. | Sigma-Aldrich | T6397 | |
| Basic fibroblast growth factor (bFGF) | See Table 14: Preparation of the basic fibroblast growth factor. | Sigma-Aldrich | F3685-25UG | |
| Collagen Type 4 | See Table 15: Preparation of the collagen solution. | Sigma-Aldrich | C5533-5MG | |
| Epidermal growth factor (EGF) | See Table 16: Preparation of the epidermal growth factor solution. | Sigma-Aldrich | E9644-.2MG | |
| Fetuin A | See Table 17: Preparation of the fetuin A (α2-hs-glycoprotein) solution. | Sigma-Aldrich | G0516-1MG | |
| Insulin-like growth factor 1 (IGF-1) | See Table 20: Preparation of the insulin-like growth factor 1 solution. | ThermoFisher Scientifica | PHG0071 | |
| Platelet-derived growth factor AA (PDGF) | See Table 21: Preparation of the platelet-derived growth factor AA solution. | PeproTechb | 100-13A | |
| Laminin | See Table 22: Preparation of the laminin solution. | Sigma-Aldrich | L6274-.5MG | |
| Vitronectin | See Table 24: Preparation of the vitronectin solution. | Stemcell Technologiesc | 07180 | |
Waltham, Massachusetts, USA. https://www.fishersci.com/.
Cranbury, New Jersey, USA. https://www.peprotech.com/.
Vancouver, British Columbia, Canada. https://www.stemcell.com/.
The basis for our medium is DMEM/F12, which was developed for cells in monolayer culture and has a bicarbonate content for the use in an incubator with 5% CO2 to obtain correct pH. Please observe that the original DMEM has a bicarbonate content that provides the correct pH when used in an incubator with 10% CO2. Thus, it should never be used in an incubator with 5% CO2, which unfortunately is found in publications and cell bank recommendations regarding medium for cell lines.
Additionally, the DMEM/F12 product mentioned here contains phenol red. Since phenol red is a xenobiotic with low estrogenic activity, a medium without phenol red would be preferred. Phenol red is added for visual pH control but with knowledge of how bicarbonate functions in pH control, phenol red can be omitted [14].
Furthermore, this medium is made for cells that require attachment and has only been tested for such cells. We have not done any studies on cells in suspension culture with the exception of human CD4+ T-cells that were activated by CD3/CD28 microbeads to stimulate cell proliferation in the defined medium using RPMI1640 instead of DMEM/F12 (not published). When using DMEM/F12, the final concentration of each (non-protein) component in our defined medium can be seen in Table 26. Our medium mimicks the complexity of human serum and industrial manufacturing will lower its production price significantly [24].
Table 26.
Composition of all non-protein components in the defined medium after supplementation of DMEM/F12 to enrich the medium.
| Component | Concentration found in DMEM/F12 | Added supplement | Final concentration in our medium |
|---|---|---|---|
| Amino Acids | |||
| Glycine | 18.75 µg/ml | 7.5 ng/ml | 18.7575 µg/ml |
| L-Alanine | 4.45 µg/ml | 8.9 ng/ml | 4.4589 µg/ml |
| L-Arginine hydrochloride | 147.5 µg/ml | — | 147.5 µg/ml |
| L-Asparagine monohydrate | 7.5 µg/ml | 15 ng/ml | 7.515 µg/ml |
| L-Aspartic acid | 6.65 µg/ml | 13.3 ng/ml | 6.6633 µg/ml |
| L-Cysteine hydrochloride monohydrate | 17.56 µg/ml | — | 17.56 µg/ml |
| L-Cystine dihydrochloride | 31.29 µg/ml | — | 31.29 µg/ml |
| L-Glutamic acid | 7.35 µg/ml | 14.7 ng/ml | 7.3647 µg/ml |
| L-Glutamine | — | 2 mM | 2 mM |
| L-Histidine hydrochloride monohydrate | 31.48 µg/ml | — | 31.48 µg/ml |
| L-Isoleucine | 54.47 µg/ml | — | 54.47 µg/ml |
| L-Leucine | 59.05 µg/ml | — | 59.05 µg/ml |
| L-Lysine hydrochloride | 91.25 µg/ml | — | 91.25 µg/ml |
| L-Methionine | 17.24 µg/ml | — | 17.24 µg/ml |
| L-Phenylalanine | 35.48 µg/ml | — | 35.48 µg/ml |
| L-Proline | 17.25 µg/ml | 11.5 ng/ml | 17.2615 µg/ml |
| L-Serine | 26.25 µg/ml | 10.5 ng/ml | 26.2605 µg/ml |
| L-Threonine | 53.45 µg/ml | — | 53.45 µg/ml |
| L-Tryptophan | 9.02 µg/ml | — | 9.02 µg/ml |
| L-Tyrosine disodium salt dihydrate | 55.79 µg/ml | — | 55.79 µg/ml |
| L-Valine | 25.85 µg/ml | — | 25.85 µg/ml |
| Vitamins | |||
| Biotin | 3.5 ng/ml | — | 3.5 ng/ml |
| Choline chloride | 8.98 µg/ml | 3.5 µg/ml | 12.48 µg/ml |
| D-Calcium pantothenate | 2.24 µg/ml | — | 2.24 µg/ml |
| Folic acid | 2.65 µg/ml | 0.33 µg/ml | 2.98 µg/ml |
| I-Inositol | 12.6 µg/ml | 4.5 µg/ml | 17.1 µg/ml |
| Niacinamide | 2.02 µg/ml | — | 2.02 µg/ml |
| Pyridoxine hydrochloride | 2 µg/ml | — | 2 µg/ml |
| Riboflavin | 219 ng/ml | — | 219 ng/ml |
| Thiamine hydrochloride | 2.17 µg/ml | 0.08 µg/ml | 2.25 µg/ml |
| α-Tocopherol phosphate | — | 3 ng/ml | 3 ng/ml |
| Vitamin B12 | 0.68 µg/ml | 0.35 µg/ml | 1.03 µg/ml |
| Inorganic Salts | |||
| Calcium chloride (CaCl2) anhydrous | 116.6 µg/ml | — | 116.6 µg/ml |
| Cupric sulfate pentahydrate (CuSO4 · 5H2O) | 1.3 ng/ml | — | 1.3 ng/ml |
| Ferric nitrate nonahydrate (Fe(NO3)3 · 9H2O) | 50 ng/ml | — | 50 ng/ml |
| Ferrous sulfate heptahydrate (FeSO4 · 7H2O) | 417 ng/ml | — | 417 ng/ml |
| Magnesium chloride (MgCl2) anhydrous | 28.64 µg/ml | — | 28.64 µg/ml |
| Magnesium sulfate (MgSO4) anhydrous | 48.84 µg/ml | — | 48.84 µg/ml |
| Potassium chloride (KCl) | 311.8 µg/ml | — | 311.8 µg/ml |
| Sodium bicarbonate (NaHCO3) | 2438 µg/ml | — | 2438 µg/ml |
| Sodium chloride (NaCl) | 6995.5 µg/ml | — | 6995.5 µg/ml |
| Sodium phosphate dibasic (Na2HPO4) anhydrous | 71.02 µg/ml | — | 71.02 µg/ml |
| Sodium phosphate monobasic monohydrate (NaH2PO4 · H2O) | 62.5 µg/ml | — | 62.5 µg/ml |
| Zinc sulfate heptahydrate (ZnSO4 · 7H2O) | 432 ng/ml | — | 432 ng/ml |
| Other Components | |||
| 4-Aminobenzoic acid | — | 12 ng/ml | 12 ng/ml |
| All-trans-retinoic acid | — | 25 ng/ml | 25 ng/ml |
| Ascorbic acid | — | 12 ng/ml | 12 ng/ml |
| Cholesterol | — | 50 ng/ml | 50 ng/ml |
| Dextrose (D-Glucose) | 3151 µg/ml | — | 3151 µg/ml |
| β-Estradiol | — | 0.5 pg/ml | 0.5 pg/ml |
| Glutathione | — | 12 ng/ml | 12 ng/ml |
| Hydrocortisone | — | 0.25 ng/ml | 0.25 ng/ml |
| Hypoxanthine monosodium | 2.39 µg/ml | — | 2.39 µg/ml |
| Lipoic acid | 105 ng/ml | 50 ng/ml | 155 ng/ml |
| Linoleic acid | — | 1 µg/ml | 1 µg/ml |
| O-Phosphorylethanolamine | — | 5 µg/ml | 5 µg/ml |
| Phenol red | 8.1 µg/ml | — | 8.1 µg/ml |
| Putrescine dihydrochloride | 81 ng/ml | — | 81 ng/ml |
| Ribose | — | 125 ng/ml | 125 ng/ml |
| Selenous acid | — | 8 ng/ml | 8 ng/ml |
| Sodium pyruvate | 0.5 mM | 1 mM | 1.5 mM |
| Thymidine | 365 ng/ml | — | 365 ng/ml |
| Triiodothyronine | — | 0.2 pg/ml | 0.2 pg/ml |
| Uracil | — | 75 ng/ml | 75 ng/ml |
| Xanthine | — | 85 ng/ml | 85 ng/ml |
Instead of coating the culture surfaces with fibronectin separately, we add fibronectin directly to the culture medium. Hence, when cells are seeded in the defined medium with fibronectin at passaging, the tissue culture surface will be covered with sufficient amounts of fibronectin. This also means that for the replacement medium in between passaging, use the medium without fibronectin as described in Rafnsdóttir et al. [14]. We have found that many cell lines do not appear to thrive when fibronectin is present in replacement medium.
Most cell culture laboratories already purchase concentrated solutions of cell culture components such as glutamine, sodium pyruvate, non-essential amino acid, and penicillin-streptomycin. We always aliquot these in 5 ml portions, which results in the desired concentration in 500 ml medium and keep the tubes frozen at −20 °C. If possible, it is good to avoid antibiotics like penicillin-streptomycin as they also are xenobiotics. The half-life of antibiotics is quite short at 37 °C, about 2 days for penicillin and about 4 days for streptomycin. When sampling medium for mycoplasma testing, the cells should be cultured for 2 weeks in antibiotics free medium. This is a test of good sterile technique and possibly stimulates the constant use of medium without antibiotics.
Some proteins needed for the defined medium are purchased as solutions and we suggest aliquoting as seen below.
When all solutions are prepared, thawed, and placed in the laminar air-flow (LAF) bench, the final mixing takes approximately 30 min for a person that is used to pipetting. Do not turn on the light in the LAF bench. As can be found in the protocols below, some components are light sensitive, and thus, the entire medium is light sensitive. The light sensitivity of media has been tested and reported and in general, all media are light sensitive [18,19]. Vitamins and retinoic acid mainly contribute to the light sensitivity [20], [21], [22]. We have not performed a systematic investigation of the light sensitivity of the defined medium but rely on published data. We have never had problems working in the LAF bench with the light off and have used the medium in courses with undergraduate students with no problems or complaints.
The complete medium is stored at 4 °C and we recommend that it is used within two months. Freezing the medium at −20 °C will extend this approximately to four months; however, we have not performed a systematic storage time test of the complete defined medium a −20 °C. Below you will find more information about aliquoting the mixed medium to minimize pH changes as well as the possibility of degradation of components with repeated warming of the medium before addition to cells.
Recommended tissue culture plastic
Most tissue culture plastic is made of polystyrene, although this material is naturally hydrophobic. It therefore poorly supports cell adhesion and cells that require attachment will die. Tissue culture plastic for cell culturing is oxygen plasma-treated resulting in the insertion of oxygen containing groups in the styrene molecules. In contact with water, ionization results in a negatively charged surface [23].
Our experience shows that cells thrive better in the defined medium when cultured on Corning3 Primaria tissue culture plastic [14]. The reason is that these plastics contain ammonium groups besides the oxygen containing groups and therefore become both positively and negatively charged in contact with water.
Mixing of the defined medium with prepared stock solutions
This is a description of how to combine the different components (see Table 3, Table 4, Table 5) with the respective solvents (see Table 6). Enclosed are individual protocols for different components. The final mixing takes approximately 30 min for a person that is used to pipetting when all components are thawed and placed in the LAF bench. Do not turn on the light in the LAF bench. The medium is light sensitive.
Table 3.
Components stored at +4 °C.
| Component | Preparation | Provider | Product number |
|---|---|---|---|
| DMEM/F12 500 ml | Purchased | Biowesta | L0090-500 |
| Insulin | Purchased | Sigma-Aldrich | I9278 |
Nuaillé, France. https://biowest.net/.
Table 6.
Solvents needed for the preparation of the medium components. Stored at +20 °C.
| Solvent | Preparation | Provider | Product number |
|---|---|---|---|
| Dimethyl sulfoxide (DMSO) | Purchased | PanReac ApliChem ITW Reagentsa | A3672,0100 |
| Ethanol gradient grade | Purchased | Sigma-Aldrich | 1.11727 |
| Phosphate-buffered saline (PBS) | Prepare and sterile filter PBS | ||
| Sodium hydroxide (NaOH) | Prepare NaOH freshly | ||
| Sterile Millipore H2O | Sterilize it by autoclaving or sterile filtering | ||
Monza, Italy. https://itwreagents.com/.
Medium components needed in the Laminar Air-Flow (LAF) bench
Please note that ergocalciferol, as mentioned in the original medium description [14] was found to be dispensable and can be dismissed.
Materials needed in the LAF bench
Automatic pipettes and tips to pipet different volumes from 10 µl to 250 µl.
Pipettes 5 and 10 ml (preferably glass pipettes to reduce environmental impact).
Sterile bottles for medium aliquoting and for collecting surplus DMEM/F12.
Procedure
-
1.
Remove 43.7 ml of the 500 ml DMEM/F12 (to compensate for added volumes). Save this surplus separately in a sterile flask. Mark well! You can collect medium in the same flask until you have enough to make more defined medium.
-
2.
Add 5 ml 200 mM L-glutamine.
-
3.
Add 5 ml 10 mM NEAA giving.
-
4.
Add 5 ml 100 mM sodium pyruvate.
-
5.
Add 5 ml penicillin-streptomycin (optional). If this is not used, re-add 5 ml of DMEM/F12.
-
6.
Add 2.5 ml transferrin solution.
-
7.
Add 100 µl insulin solution.
-
8.
Turn off the light in the LAF bench.
-
9.
Thaw the Eppendorf tubes kept at −80 °C in the dark until they reach room temperature. Spin at 2000 g for 30 s before pipetting to the medium.
-
10.
Add 20 ml of the HSA solution. Mix well.
-
11.
Now we usually divide the medium into two sterile 250 ml bottles. Label one bottle: “Defined medium without fibronectin for medium replacement” plus date. Caution: Fibronectin needs to be thawed slowly without disturbance at 37 °C to prevent clumping/precipitation.
-
12.
Label the other bottle: “Defined medium with fibronectin for passaging” plus date. Add 250 µl fibronectin solution to this flask. Keep the remaining fibronectin at 4 °C. It can be stored at 4 °C for 3 months.
-
13.
If you decide to make 500 ml defined medium with fibronectin, skip the steps 11 and 12 and add 500 µl of the fibronectin solution instead.
-
14.
Store at 4 °C for a maximum of 2 months or freeze at −20 °C for 4 months.
Mixing of solutions with small organic and inorganic molecules
A number of proteins and chemicals are purchased as powders and below are protocols for making solutions. An important part of making solutions from powdery compounds is the possibility to weight with a high precision scale to reach a satisfactory accuracy and reproducibility. The scale we use has a precision of 0.00001 g. However, we recommend not weighing less than 100 µg.
Please note that before weighing laboratory materials stored below room temperature, allow these to come to room temperature. Otherwise, mass errors could occur due to condensation.
Be beware of the fact, that weighing small and precise masses of solids is more challenging than pipetting small and precise volumes of liquids. Therefore, to keep the concentration at the desired level, it might be easier to add the liquid amount according to the weighed solid mass. It is preferable to weigh slightly more than the exact amounts suggested below in the protocols, to not fall below the needed volume for the subsequent steps.
For instance: To receive a desired concentration of 0.2 µg/µl, you need to add precisely 1000 µg of solid Y to precisely 5000 µl of liquid X. If you have weighed 1094 µg of solid Y instead, you could receive the exact same desired concentration by adding 5470 µl of liquid X.
Example of calculating the volume:
Keep this in mind when preparing all compounds that need weighing.
How to prepare the stock solutions
Here you can find the protocols for the separate stock solutions. Once they are prepared, you just have to thaw and mix them according to the 14-step procedure mentioned above. An excel sheet for ticking off compounds while mixing the medium can be found in the supplementary materials.
Table 7.
Preparation of the ethanol solution.
| Product | Supplemented concentration | Amount in the aliquot (25 µl) |
|---|---|---|
| 4-Aminobenzoic acid | 12 ng/ml | 6.0 µg |
| Cholesterol | 50 ng/ml | 25 µg |
| Lipoic acid | 50 ng/ml | 25 µg |
| Linoleic acid | 1 µg/ml | 500 µg |
| General Information | ||
| These compounds are soluble in gradient grade ethanol. Thus, start by preparing a stock solution for each compound for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 8.
Preparation of the NaOH solution.
| Product | Supplemented concentration | Amount in the aliquot (50 µl) |
|---|---|---|
| Folic acid | 330 ng/ml | 165 µg |
| Uracil | 75 ng/ml | 37.5 µg |
| Xanthine | 85 ng/ml | 42.5 µg |
| General Information | ||
| These compounds are soluble in NaOH. Thus, start by preparing a stock solution for each compound for receiving the supplemented concentration in 500 ml defined medium as shown above. Then combine these according the instructions. | ||
Preparation
| ||
Table 9.
Preparation of the H2O solution.
| Product | Supplemented concentration | Amount in the aliquot (200 µl) |
|---|---|---|
| Ascorbic acid | 12 ng/ml | 6 µg |
| Choline chloride | 3.5 µg/ml | 1.75 mg |
| Glutathione | 12 ng/ml | 6 µg |
| I-Inositol | 4.5 µg/ml | 2.25 mg |
| O-Phosphorylethanolamine | 5 µg/ml | 2.5 mg |
| Ribose | 125 ng/ml | 62.5 µg |
| Selenous acid | 8 ng/ml | 4 µg |
| Thiamine hydrochloride | 80 ng/ml | 40 µg |
| α-Tocopherol phosphate | 3 ng/ml | 1.5 µg |
| Vitamin B12 | 0.35 µg/ml | 175 µg |
| General Information | ||
| These compounds are soluble in H2O. Thus, start by preparing a stock solution for each compound for receiving the supplemented concentration in 500 ml defined medium as shown above. Then combine these according the instructions. Some compounds are light sensitive. Work under subdued light. | ||
Preparation
| ||
Table 10.
Preparation of the all-trans retinoic acid solution.
| Product | Supplemented concentration | Amount in the aliquot (10 µl) |
|---|---|---|
| All-trans-retinoic acid | 25 ng/ml | 12.5 µg |
| General Information | ||
| All-trans-retinoic acid is highly light sensitive and sensitive to air. Work in subdued light i.e. turn off the light in the LAF bench and dim the light in the room. Do not work with powder or concentrated all-trans-retinoic acid if you are pregnant. The compound is teratogenic. Dissolve all retinoic acid. Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
| Note | ||
| All-trans-retinoic acid may not be required for some cell lines that can be induced to differentiate by retinoic acid treatment. However, the all-trans-retinoic acid concentration used here is very low (83.3 nM) compared to the concentrations used when inducing differentiation e.g. in SH-SY5Y neuroblastoma cells (1–10 µM). | ||
Table 11.
Preparation of the β-estradiol solution.
| Product | Supplemented concentration | Amount in the aliquot (10 µl) |
|---|---|---|
| β-Estradiol | 0.5 pg/ml | 250 ng |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 12.
Preparation of the hydrocortisone solution.
| Product | Supplemented concentration | Amount in the aliquot (20 µl) |
|---|---|---|
| Hydrocortisone | 0.25 ng/ml | 125 ng |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 13.
Preparation of the triiodothyronine solution.
| Product | Supplemented concentration | Amount in the aliquot (10 µl) |
|---|---|---|
| Triiodothyronine | 0.2 pg/ml | 0.1 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Here you will find the protocols for the protein solution stocks
Table 14.
Preparation of the basic fibroblast growth factor.
| Product | Supplemented concentration | Amount in the aliquot (50 µl) |
|---|---|---|
| Basic Fibroblast Growth Factor (bFGF) | 1 ng/ml | 0.5 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 15.
Preparation of the collagen solution.
| Product | Supplemented concentration | Amount in the aliquot (100 µl) |
|---|---|---|
| Collagen Type 4 | 100 ng/ml | 50 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 16.
Preparation of the epidermal growth factor solution.
| Product | Supplemented concentration | Amount in the aliquot (250 µl) |
|---|---|---|
| Epidermal Growth Factor (EGF) | 10 ng/ml | 5 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 17.
Preparation of the fetuin A (α2-hs-glycoprotein) solution.
| Product | Supplemented concentration | Amount in the aliquot (50 µl) |
|---|---|---|
| Fetuin A | 40 ng/ml | 20 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 18.
Preparation of the fibronectin solution.
| Product | Supplemented concentration | Amount in the aliquot (500 µl) |
|---|---|---|
| Fibronectin | 1.33 µg/ml | 655 µg |
| General Information | ||
| Fibronectin is tricky to solve. Be very patient. Do never shake! Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
| Note | ||
| The thawing of fibronectin must be gentle! Take a tube and keep it in the incubator at 37 °C for 1 h. Do not shake. | ||
Table 19.
Preparation of PBS with 0.1 % human serum albumin (HSA).
| Product |
|---|
| PBS + Human Serum Albumin (HSA) |
| General Information |
| This is needed to prepare the IGF-1, PDGF, and laminin solutions (see Table 20, Table 21, and Table 22, respectively). |
Preparation
|
Table 20.
Preparation of the insulin-like growth factor 1 solution.
| Product | Supplemented concentration | Amount in the aliquot (25 µl) |
|---|---|---|
| Insulin-like growth factor 1 (IGF-1) | 5 ng/ml | 2.5 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 21.
Preparation of the platelet-derived growth factor AA solution.
| Product | Supplemented concentration | Amount in the aliquot (50 µl) |
|---|---|---|
| Platelet-derived growth factor AA (PDGF) | 2 ng/ml | 1 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 22.
Preparation of the laminin solution.
| Product | Supplemented concentration | Amount in the aliquot (50 µl) |
|---|---|---|
| Laminin | 20 ng/ml | 10 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 23.
Preparation of the transferrin solution.
| Product | Supplemented concentration | Amount in the aliquot (2.5 ml) |
|---|---|---|
| Transferrin | 50 µg/ml | 25 mg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
| Caution | ||
| Be careful not to lose any of the powder. Clumps easily remain stuck inside the pipette used for mixing. To prevent this, use two 10 ml pipettes. One for adding the sterile Millipore H2O and one for transferring to the glass bottle. When adding Millipore H2O to the bottle with powder, keep the transferring pipette in the 100 ml bottle. | ||
Table 24.
Preparation of the vitronectin solution.
| Product | Supplemented concentration | Amount in the aliquot (200 µl) |
|---|---|---|
| Vitronectin | 100 ng/ml | 50 µg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
Table 25.
Preparation of the human serum albumin (HSA) solution for the defined medium.
| Product | Supplemented concentration | Amount in the aliquot (20 ml) |
|---|---|---|
| Human Serum Albumin (HSA) | 1.25 mg/ml | 625 mg |
| General Information | ||
| Prepare a stock solution for receiving the supplemented concentration in 500 ml defined medium as shown above. | ||
Preparation
| ||
| Note | ||
| Thaw slowly and never shake. | ||
Prepare small plastic zip-lock bags with tubes stored at −80 °C
This steps makes it easier to collect the tubes needed when making the defined medium. To avoid thawing, it is recommended to keep all components on dry ice while preparing the bags.
-
1.Label the bags with:
-
-H2O
-
-NaOH
-
-Ethanol
-
-Collagen
-
-β-Estradiol
-
-EGF
-
-bFGF
-
-Fetuin A
-
-Hydrocorisone
-
-IGF1
-
-Laminin
-
-PDGF
-
-Retinoic acid
-
-Triiodothyronine
-
-Vitronectin
-
-
-
2.
Add tubes to the bags.
-
3.
Store at −80 °C.
Ethics statements
There are no ethical considerations regarding this work. No human subjects or animals are used. No data is collected from social media platforms.
CRediT authorship contribution statement
Tilo Weber: Conceptualization, Writing – review & editing. Jeffrey Bajramovic: Writing – review & editing. Stina Oredsson: Conceptualization, Methodology, Writing – review & editing.
Acknowledgments
This research could not have been done without funding from Forska Utan Djurförsök, Stockholm, Sweden (https://forskautandjurforsok.se/, grant number F2020-002), and donations through crowd funding by Carolina le Prince and the Kalenderflickorna (https://www.lu.se/artikel/kalenderflickor-i-cancerforskningens-tjanst/), Bröstcancerföreningen Pärlan Helsingborg, Ramlösa, Sweden (https://helsingborg.brostcancerforbundet.se/), Bröstcancerföreningen Viktoria Ängelholm, Hjärnarp, Sweden (https://angelholm.brostcancerforbundet.se/), as well as Stig and Lisa Ekelund and Mari-Ann and Brainerd Lindberg via Lund University Development Office, Lund, Sweden. The sponsors have no other role than providing funding.
Credits go to Kristina Kostova (https://www.kriskostova.com/) for designing and drawing the graphical abstract.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Related research article: Ó.B. Rafnsdóttir, A. Kiuru, M. Tebäck, N. Friberg, P. Revstedt, J. Zhu, S. Thomasson, A. Czopek, A. Malakpour-Permlid, T. Weber, S. Oredsson, A new animal product free defined medium for 2D and 3D culturing of normal and cancer cells to study cell proliferation and migration as well as dose response to chemical treatment, Toxicol. Rep. 10 (2023) 509-520, doi:10.1016/j.toxrep.2023.04.001.
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.mex.2024.102592.
Milford, Massachusetts, USA. https://www.seracare.com/.
Vienna, Austria. https://tht-biomaterials.com/.
Corning, New York, USA. https://www.corning.com/.
Appendix. Supplementary materials
Data availability
Data will be made available on request.
References
- 1.Yao T., Asayama Y. Animal-cell culture media: history, characteristics, and current issues. Reprod. Med. Biol. 2017;16(2):99–117. doi: 10.1002/rmb2.12024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transf. Med. Hemother. 2013;40(5):326–335. doi: 10.1159/000354061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Henschler R., Gabriel C., Schallmoser K., Burnouf T., Koh M.B.C. Human platelet lysate current standards and future developments. Transfusion. 2019;59(4):1407–1413. doi: 10.1111/trf.15174. [DOI] [PubMed] [Google Scholar]
- 4.Cassotta M., Bartnicka J.J., Pistollato F., Parvatam S., Weber T., D'Alessandro V., Bastos L.F., Coecke S. A worldwide survey on the use of animal-derived materials and reagents in scientific experimentation. Eng. Life Sci. 2022;22(9):564–583. doi: 10.1002/elsc.202100167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Paim W.P., Maggioli M.F., Falkenberg S.M., Ramachandran A., Weber M.N., Canal C.W., Bauermann F.V. Virome characterization in commercial bovine serum batches —A potentially needed testing strategy for biological products. Viruses. 2021;13(12):2425. doi: 10.3390/v13122425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Zhang P., Cao L., Ma Y.Y., Su B., Zhang C.Y., Li Y.P. Metagenomic analysis reveals presence of different animal viruses in commercial fetal bovine serum and trypsin. Zool. Res. 2022;43(5):756–766. doi: 10.24272/j.issn.2095-8137.2022.093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.van der Valk J., Bieback K., Buta C., Cochrane B., Dirks W.G., Fu J., Hickman J.J., Hohensee C., Kolar R., Liebsch M., Pistollato F., Schulz M., Thieme D., Weber T., Wiest J., Winkler S., Gstraunthaler G. Fetal bovine serum (FBS): past – present – future. ALTEX. 2018;35(1):99–118. doi: 10.14573/altex.1705101. [DOI] [PubMed] [Google Scholar]
- 8.van der Valk J. Fetal bovine serum—A cell culture dilemma. Science. 2022;375(6577):143–144. doi: 10.1126/science.abm1317. [DOI] [PubMed] [Google Scholar]
- 9.Weber T., Wiest J., Oredsson S., Bieback K. Case studies exemplifying the transition to animal component-free cell culture. Altern. Lab. Anim. 2022;50(5):330–338. doi: 10.1177/02611929221117999. [DOI] [PubMed] [Google Scholar]
- 10.Weber T., Wirths F., Brakebusch N., van der Valk J. Reply to comment “Animal welfare and ethics in the collection of fetal blood for the production of fetal bovine serum. ALTEX. 2021;38(2):324–326. doi: 10.14573/altex.2103191. [DOI] [PubMed] [Google Scholar]
- 11.McCann T.J., Treasure C. Addressing animal welfare issues in fetal blood collection for fetal bovine serum production. Altern. Lab. Anim. 2022;50(5):365–368. doi: 10.1177/02611929221117992. [DOI] [PubMed] [Google Scholar]
- 12.Reichstein I.S., König M., Wojtysiak N., Escher B.I., Henneberger L., Behnisch P., Besselink H., Thalmann B., Colas J., Hörchner S., Hollert H., Schiwy A. Replacing animal-derived components in in vitro test guidelines OECD 455 and 487. Sci. Total Environ. 2023;868 doi: 10.1016/j.scitotenv.2023.161454. [DOI] [PubMed] [Google Scholar]
- 13.Duarte A.C., Costa E.C., Filipe H.A.L., Saraiva S.M., Jacinto T., Miguel S.P., Ribeiro M.P., Coutinho P. Animal-derived products in science and current alternatives. Biomater. Adv. 2023;151 doi: 10.1016/j.bioadv.2023.213428. [DOI] [PubMed] [Google Scholar]
- 14.Rafnsdóttir Ó.B., Kiuru A., Tebäck M., Friberg N., Revstedt P., Zhu J., Thomasson S., Czopek A., Malakpour-Permlid A., Weber T., Oredsson S. A new animal product free defined medium for 2D and 3D culturing of normal and cancer cells to study cell proliferation and migration as well as dose response to chemical treatment. Toxicol. Rep. 2023;10:509–520. doi: 10.1016/j.toxrep.2023.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., Onder T.T., Wang Z.C., Richardson A.L., Weinberg R.A., Orimo A. Autocrine TGF- β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. 2010;107(46):20009–20014. doi: 10.1073/pnas.1013805107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Maity N., Jaswal A.S., Gautam A., Sahai V., Mishra S. High level production of stable human serum albumin in Pichia pastoris and characterization of the recombinant product. Bioprocess Biosyst. Eng. 2022;45(2):409–424. doi: 10.1007/s00449-021-02670-z. [DOI] [PubMed] [Google Scholar]
- 17.Hackethal J., Schuh C.M.A.P., Hofer A., Meixner B., Hennerbichler S., Redl H., Teuschl A.H. In: Novel Biomaterials for Regenerative Medicine: Advances in Experimental Medicine and Biology. Chun H., Park K., Kim C.H., Khang G., editors. Springer; 2018. Human placenta laminin-111 as a multifunctional protein for tissue engineering and regenerative medicine; pp. 3–17. eds. [DOI] [PubMed] [Google Scholar]
- 18.Nielsen H.I., Bertheussen K. In: Production of Biologicals from Animal Cells in Culture. Griffiths J.B., Meignier B., editors. Butterworth-Heinemann; 1991. Degrading effect of light on cell culture media; pp. 82–84. eds. [DOI] [Google Scholar]
- 19.Neutsch L., Kroll P., Brunner M., Pansy A., Kovar M., Herwig C., Klein T. Media photo-degradation in pharmaceutical biotechnology - impact of ambient light on media quality, cell physiology, and IgG production in CHO cultures. J. Chem. Technol. Biotechnol. 2018;93(8):2141–2151. doi: 10.1002/jctb.5643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Frickel F. In: The Retinoids. Sporn M.B., Roberts A.B., Goodman D.S., editors. Academic Press; 1984. Chemistry and physical properties of retinoids; pp. 7–145. eds. [DOI] [Google Scholar]
- 21.Barua A.B., Furr H.C. Properties of retinoids. Mol. Biotechnol. 1998;10(2):167–182. doi: 10.1007/bf02760863. [DOI] [PubMed] [Google Scholar]
- 22.Schnellbaecher A., Binder D., Bellmaine S., Zimmer A. Vitamins in cell culture media: stability and stabilization strategies. Biotechnol. Bioeng. 2019;116(6):1537–1555. doi: 10.1002/bit.26942. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Malakpour-Permlid A., Oredsson S. In: 3D Lung Models for Regenerating Lung Tissue. Westergren-Thorsson G., Enes S.R., editors. Academic Press; 2022. Two-dimensional cell culturing on glass and plastic: the past, the present, and the future; pp. 21–35. eds. [DOI] [Google Scholar]
- 24.Ali A.S.M., Berg J., Roehrs V., Wu D., Hackethal J., Braeuning A., Woelken L., Rauh C., Kurreck J. Xeno-Free 3D Bioprinted Liver Model for Hepatotoxicity Assessment. Int. J. Mol. Sci. 2024;25(3):1811. doi: 10.3390/ijms25031811. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data will be made available on request.


